Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$12.93 - $43.32
Next Earnings Date
May 07 2025
Next Earnings Date
May 07 2025
Latest price
Market Cap | $5.74B |
EV | $5.68B |
Shares Outstanding | 149.01M |
Beta | 2.14 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $43.00 |
P/E 2025E | 37.97x |
P/Revenue 2025E | 10.36x |
Revenue | 266.40% |
EPS | - |
Operating Cash Flow | 48.40% |
Free Cash Flow | 48.50% |
Revenue | 43.30% |
EPS | 156.80% |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 86.75% |
Net Profit Margin 2025E | 30.22% |
ROE 2025E | 50.96% |
ROCE 2024 | 12.21% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
TG Therapeutics, Inc.
TGTX
Sector
Healthcare
Industry
Biotechnology
CEO
Weiss, Michael
Employees
338
Website
www.tgtherapeutics.comIPO Date
2010-05-03
Headquarters
3020 Carrington Mill Blvd., Suite 475, Morrisville, North Carolina, 27560, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved